Standard BioTools Inc
NASDAQ:LAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Standard BioTools Inc
Net Income (Common)
Standard BioTools Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Standard BioTools Inc
NASDAQ:LAB
|
Net Income (Common)
-$74.9m
|
CAGR 3-Years
27%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-3%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Net Income (Common)
$6.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
13%
|
|
|
Danaher Corp
NYSE:DHR
|
Net Income (Common)
$3.7B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
0%
|
|
|
Waters Corp
NYSE:WAT
|
Net Income (Common)
$642.6m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Net Income (Common)
$1.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Net Income (Common)
$1.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
37%
|
CAGR 10-Years
13%
|
|
Standard BioTools Inc
Glance View
Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.
See Also
What is Standard BioTools Inc's Net Income (Common)?
Net Income (Common)
-74.9m
USD
Based on the financial report for Dec 31, 2025, Standard BioTools Inc's Net Income (Common) amounts to -74.9m USD.
What is Standard BioTools Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-3%
Over the last year, the Net Income (Common) growth was 59%. The average annual Net Income (Common) growth rates for Standard BioTools Inc have been 27% over the past three years , -7% over the past five years , and -3% over the past ten years .
